Drugs / BI 34021 FU2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02259842 | Mar → Jun 2008 | — | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 34021 FU2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02259842 ↗ |
| Route | Oral | “Evaluation of safety, tolerability and PK of single rising oral doses of BI 34021 FU2 in healthy male volunteers” NCT02259842 ↗ |